Connor, Clark & Lunn Investment Management (CC&L)’s Immunovant IMVT Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.5M	Buy	503,673 +36,204	+8%	+$937K	0.03%	425
2025 Q4	$11.9M	Sell	467,469 -91,428	-16%	-$2.04M	0.03%	415
2025 Q3	$9.01M	Buy	558,897 +110,382	+25%	+$1.79M	0.03%	435
2025 Q2	$7.18M	Buy	448,515 +84,286	+23%	+$1.27M	0.03%	488
2025 Q1	$6.22M	Buy	364,229 +128,345	+54%	+$2.68M	0.03%	445
2024 Q4	$5.84M	Buy	235,884 +54,085	+30%	+$1.53M	0.03%	446
2024 Q3	$5.18M	Sell	181,799 -56,789	-24%	-$1.67M	0.03%	423
2024 Q2	$6.3M	Buy	238,588 +94,203	+65%	+$2.68M	0.03%	375
2024 Q1	$4.67M	Sell	144,385 -5,855	-4%	-$214K	0.02%	447
2023 Q4	$6.33M	Sell	150,240 -96,942	-39%	-$3.57M	0.03%	359
2023 Q3	$9.49M	Buy	247,182 +99,378	+67%	+$2.25M	0.05%	256
2023 Q2	$2.8M	Buy	147,804 +85,421	+137%	+$1.59M	0.01%	521
2023 Q1	$968K	Buy	62,383 +36,164	+138%	+$628K	0.01%	723
2022 Q4	$465K	Buy	26,219 +7,867	+43%	+$99.1K	﹤0.01%	878
2022 Q3	$102K	Buy	+18,352	New	+$89.7K	﹤0.01%	1040
2022 Q2	–	Sell	-44,668	Closed	-$246K	–	1114
2022 Q1	$246K	Sell	44,668 -110,373	-71%	-$687K	﹤0.01%	912
2021 Q4	$1.32M	Buy	155,041 +76,990	+99%	+$636K	0.01%	627
2021 Q3	$678K	Buy	+78,051	New	+$704K	﹤0.01%	710